- 1 Evaluation of tooth sensitivity after scaling and root planing treated with photobiomodulation: a
- 2 randomized controlled split-mouth double-blind clinical protocol
- 3
- 4 Short title: Tooth sensitivity after scaling and root planing treated with photobiomodulation
- 5
- 6 María Victoria García Olazabal<sup>1,2,#b,#a,¶</sup> garciaolazabal@gmail.com
- 7 Luis Eduardo Pascuali Moya<sup>1,2,#a,#b,¶</sup> <u>dr.luisepm@gmail.com</u>
- 8 Rolf Wilhem Consolandich Cirisola<sup>1,2,#a,#b,¶</sup> drconsolandich@gmail.com
- 9 Ana Paula Taboada Sobral<sup>3,#c, &</sup> anapaula@taboada.com.br
- 10 Laura Hermida Bruno<sup>1,2,#b,#a,¶</sup> <u>laurahermidabruno@gmail.com</u>
- 11 Federico Todeschini Safi<sup>1,2,#b,#a,¶</sup> <u>federico.todeschini@ucu.edu.uy</u>
- 12 Priscila Larcher Longo <sup>4,#d,#a,¶</sup> <u>pllongo@gmail.com</u>
- 13 Maria Cristina Chavantes<sup>1#a,&</sup> <u>lunglasertherapy@yahoo.com.br</u>
- 14 Ricardo Scarparo Navarro <sup>5,#e¶</sup> <u>ricardosnavarro@gmail.com</u>
- 15 Cinthya Cosme Gutierrez Duran<sup>1#a,&</sup> <u>cduran@uni9.pro.br</u>
- 16 Kristianne Porta Santos Fernandes<sup>1#a,&</sup> kristianneporta@gmail.com
- 17 Raquel Agnelli Mesquita Ferrari<sup>1#a,&</sup> <u>raquel.mesquita@gmail.com</u>
- 18 Sandra Kalil Bussadori<sup>1#a,&</sup> <u>sandra.skb@gmail.com</u>
- 19 Lara Jansiski Motta<sup>1#a,&</sup> <u>larajmotta@uni9.pro.br</u>
- 20 Anna Carolina Ratto Tempestini Horliana<sup>1#a¶\*</sup> annacrth@gmail.com
- 21
- 22 <sup>1</sup>Postgraduate Program in Biophotonics Applied to Health Sciences, Universidade Nove de
- 23 Julho (UNINOVE), São Paulo, Brazil.
- <sup>2</sup>Universidad Católica del Uruguay (UCU), Montevideo, Uruguay.
- <sup>3</sup>Postgraduation Program in Health and Environment, Universidade Metropolitana de Santos,
- 26 Santos, Brazil
- <sup>4</sup>Postgraduate Program in Aging Science, Universidade São Judas Tadeu (USJT), São Paulo,
- 28 Brazil
- 29 <sup>5</sup> Universidade Brasil, São Paulo, Brazil
- 30
- 31 <sup>#a</sup> Current adress: Universidade Nove de Julho (UNINOVE), São Paulo, Brazil.
- 32 <sup>#b</sup> Current adress: Universidad Católica del Uruguay (UCU), Montevideo, Uruguay
- 33 <sup>#c</sup> Current adress: School of Dentistry, Universidade Metropolitana de Santos, Santos, Brazil
- 34 NOTE (This preprint reggets not versitely bashes if other incartified (by 8997), Savapathe in the set of guide clinical practice.

- <sup>#e</sup> Current adress: Universidade Brasil, São Paulo, Brazil 1
- 2 3 ¶ These authors contributed equally to this work.
- 4 & These authors also contributed equally to this work.
- 5
- 6 **Corresponding Author:**
- 7 E-mail: annacrth@gmail.com (ACRTH)
- Orcid iD: 0000-0003-3476-9064 8
- 9 Data availability Statement- all data will be available for the readers.
- Funding Statement The project received a government grant (National Council for 10 • Scientific and Technological Development – CNPq- process: 3146682020-9). In this 11 study the funder only will provide support and resources but will not hold ultimate 12 authority over study design, data collection, analysis, report writing, or publication 13 decisions, ensuring scientific integrity and independence 14
- 15 Conflict of interest disclosure All authors disclose any financial and personal • relationships with other people or organizations that could inappropriately influence 16 (bias) this study. 17
- Ethics approval Statement The project received approval from the Research Ethics 18 Committee of Universidad Católica del Uruguay (UCU), (process: 30052022) 19
- 20 **Patient consent Statement** – All the participants included signed an Informed consent. The CI document was in writing. 21
- Clinical trial registration: NCT05946265 (initial release: July 2023) 22 •
- **Dissemination policy** We will disseminate the trial findings to participants, healthcare 23 • 24 professionals, and the general public. Comprehensive data, along with results, will be shared through both complete datasets and results databases while adhering to any 25 publication restrictions. Moreover, we are committed to facilitating potential public 26 27 access to the full protocol, participant-level dataset, and statistical code. These measures emphasize our unwavering dedication to maintaining transparency 28
- Author contributions: Conceptualization; Horliana ACRT, Fernandes KPS, Motta LJ, 29 . 30 Bussadori SK; Methodology: Horliana ACRT, Mesquita-Ferrari AR, Sobral APT; Project 31 administration; Bussadori SK; Cirisola RWC; Resources Olazabal MVG, Safi FT; Supervision; Fernandes KPS, Bussadori SK, Mesquita-Ferrari AR; Navarro RS; 32 33 Validation; Motta LJ, Mesquita-Ferrari AR; Bruno LH, Chavantes MC, Duran CCG; Roles/Writing Moya LEP, Cirisola RWC Olazabal MVG; Longo PL 34

35

#### 1 Abstract

2

It is well known that hypersensitivity affects patients recently treated with scaling and root 3 4 planing. Some studies have demonstrated that photobiomodulation (PBM) can alleviate dentinal hypersensitivity by modulating pain. However, to date, there is no established protocol for its 5 application after scaling and root planning. To evaluate tooth hypersensibility after 6 7 photobiomodulation in sensitive scaling and root planning treated teeth. Study design: 8 Randomized, controlled, double-blind split-mouth clinical trial. Methods: Forty-four patients 9 with dentin sensibility after non-surgical scaling and root planning (SRP) will be randomly included in 2 groups: Experimental Group: SRP+ Photobiomodulation (PBM) (660nm, 100W, 10 11 area 0,5cm<sup>2</sup>, 200w/cm<sup>2</sup>, 30 seconds, 3 J, 6J/cm<sup>2</sup>) and Control Group: Scaling and root planning +FBM simulation. After 7 days of scaling and root planning, all patients will be evaluated for 12 hypersensibility. The cutoff of VAS will be 3. These patients will be included in the study. The 13 primary outcome of the study will be the assessment of dentin hypersensitivity after 7 days of 14 15 RAR measured with the visual analog scale (VAS). Also, it will be assessed the impact of oral 16 health on the participant's quality of life, with the OHIP-14 questionnaire. The use of analgesics 17 (paracetamol) will be prescribed as needed and the amount of medication will be calculated. 18 These outcomes will be evaluated after 7 days and 1 month of application. If the data are normal, 19 they will be submitted to the ANOVA test – one way. Data will be presented as means  $\pm$  SD and 20 the p-value will be set to < 0.05.

21

22 Keywords: photobiomodulation, periodontal treatment, low-level light therapy, Dentin23 Sensitivity

24

### 25 Introduction

Periodontitis is a disease associated with subgingival biofilm adhered to tooth surfaces,
which generates a chronic inflammatory response that is unable to interrupt the infectious process
and causes progressive destruction of the supporting periodontium (Papapanou et al. 2018).

Periodontal therapy for the management of chronic periodontitis requires non-surgical or surgical intervention to establish healthy periodontal conditions (Alpiste 2006). However, active periodontal therapy causes undesirable sequelae, such as gingival recession or exposure of dentinal tubules, which causes dentin hypersensitivity (Romero 2009). In a previous study (Sobral et al., 1992), of 32 patients with dentin hypersensitivity, 41% had received periodontal treatment

and of these, 29% had undergone periodontal surgery. Another study (Hastings 2002) reported 1 that dentin hypersensitivity after periodontal surgery can last for months or indefinitely. Pain 2 3 arising from the exposed root surface is the most common complaint of patients after undergoing 4 periodontal therapy, however, there is little clinical research dedicated to its treatment (Raut 2018, 5 Corona 2003, Hastings 2002, Sobral 1999, Fischer 1992). To handle hypersensitivity, treatment with lasers has been proposed (Sgolastra 2013). Laser 6 7 mechanism action at hypersensitivity is not clearly understood, although several theories have been proposed. High-power lasers (e.g. Er: YAG, Nd: YAG and Er, Cr: YSSG) can reduce or 8 9 obliterate dentinal tubules by the melting effect on the superficial heat production in cementum 10 (Sgolastra et al., 2011). As for low-intensity lasers, photobiomodulation (FBM) in the dental pulp 11 can cause increased cellular metabolic activity of odontoblasts, intensifying the production of tertiary dentin, causing obliteration of dentinal tubules (Sgolastra 2013, Ladalardo 2004). 12 13 The advantage of using low-power lasers is that they are safer, do not emit heat, and are

14 more accessible for clinical practitioners (Ladalardo 2004). For these reasons, the objective of 15 this study will be to evaluate tooth sensitivity after photobiomodulation in sensitive scaling and 16 root-planning-treated teeth.

17

#### Material e métodos 18

19

This is a randomized, controlled, double-blind split-mouth clinical trial. It was designed according 20 21 to the SPIRIT Statement (Figure 1). It was submitted and accepted by the Research Ethics 22 Committee (CEP) of the Catholic University of Uruguay (#30052022). The treatments will be 23 carried out at the Periodontology Clinic II, of the Catholic University of Uruguay in the city of 24 Montevideo, Uruguay, from September 2023 to June 2024. The project has been registered on the 25 ClinicalTrials.gov website (NTC05924204) on 06th June 2023. It is not expected to change the protocol, howev, er any important protocol modifications will be communicated to the Ethical 26 27 Committee and Clinical Trial Registry. This study does not include minors. All the participants 28 provided informed consent (written and verbal). This document was approved by our Ethics Committee. This study does not report a retrospective study of medical records or archived 29 samples. Any future changes to the study will be promptly reported to the CEP and will be 30 disclosed in subsequent publications. A signed copy of the informed consent form will be 31 provided to each participant. 32

33 Sample description - Participants in need of periodontal treatment (scaling and root planning) who seek the service of the Clinic of Periodontics II at the Catholic University of Uruguay with 34 35 a diagnosis of Periodontitis, stage I, II III, or IV will be recruited by researcher 2. All patients

included will receive initial periodontal therapy (educational and preventive interventions and
removal of local retentive factors) and the second stage (Scraping and root planning). After a
week, they will be probed in the cervical region of all teeth and if there is pain greater than 3 on
the VAS, they will be included in the study.

*Inclusion and exclusion criteria* - Patients over 18 years of age, both genders, without
comorbidities, will be included. Patients who are taking drugs that affect gingival metabolism
(cyclosporine, phenytoin, nifedipine), inflammatory medicine (: corticosteroids or non-steroidal
anti-inflammatory drugs), or analgesics, pregnant or lactating women, those with photosensitivity
history and allergic to paracetamol will be excluded.

10 *Sample size calculation* - The sample size will be 22 patients in each group. This value was 11 calculated to provide a power of 90% ( $\alpha = 0.05$ ). To determine the necessary n for each group, a 12 sample calculation was performed based on a similar previous study (Ko 2014) which evaluated 13 the outcome pain decrease, measured with the VAS scale. In this study (Ko, 2014) we considered 14 an average of 3 for the experimental group and 5 for the control group. The standard deviation 15 considered for the calculation was  $\pm 2$ , the highest among the groups. A total of 22 patients will 16 be required for each group which totalizes 44 hemiarc (Split mouth).

*Examiner training* – The main researcher will be trained to use the visual analogue scale and
collect data from the OHIP-14, aiming to maximize the reproducibility of the evaluations.

19 Randomization: We will random website use а sequence generator 20 (https://www.sealedenvelope.com/) and select the randomization option of 24 blocks with 2 21 hemiarcs. The randomization will be implemented on the right side, and the opposite treatment will be applied on the left side. Opaque envelopes will be numbered sequentially and each will 22 contain information about the corresponding group based on the generated order. These envelopes 23 24 will remain sealed in a secure location until the moment of interventions with FBM or simulation. 25 The randomization process will be managed by an individual who is not directly involved in the 26 study. We have included an additional 6 hemiarches in the sample (44 hemiarches in total) to 27 account for potential losses.

28 Blinding - Immediately after periodontal treatment, the researcher responsible for applying the 29 FBM will remove and open one envelope and perform the indicated procedure (FBM or simulation). Only this researcher will know the intervention applied to each patient (Researcher 30 1). All the other investigators will be blinded to the intervention (researcher 2 - recruitment and 31 32 researcher 3 - data collection/outcomes) Allocation will not be revealed to participants during the 33 study. I will ensure the confidentiality of personal data for potential and enrolled participants 34 through secure collection, sharing, and maintenance protocols, utilizing a computer with no internet access, password protection, and data encryption stored on a USB drive 35

Pre-treatment assessments - Anamnesis, and periodontal examination will be performed. All 1 2 participants will receive guidance on oral hygiene (HBO), brushing with the Bass technique, specifications regarding the toothbrush (soft bristles and small head), dental floss (traditional 3 4 Colgate<sup>®</sup>), and scaling and root planning treatment. After one week, periodontal probing will be 5 performed before laser (or simulation application) on treated teeth to assess sensitivity (>3- VAS 6 scale) after root scaling.

7 All activity performed will be recorded, as well as the amount of medication ingested for pain sensitivity, besides OHIP-14 questionaries. 8

9 Composition of the groups - The 44 hemiarc (22 patients) will be allocated into the groups as 10 follows:

*Experimental Group* – RAR + FBM (n=22): The researcher responsible for FBM will remove the 11

12 randomization envelope and apply Laser Therapy XP (Figure 2) at the points indicated in Figure

3. All dosimetric parameters, details of sessions, and the number of FBM applications are 13

described in Table 1. 14

15 The equipment description, dosimetric parameters, and number of FBM applications are detailed in Table 1.

Dosimetric parameters	Values/treatment			
Wavelength [nm]	660 nm			
Operating mode	Continuous			
Radiant power [mW]	100 mW / 0.1 W			
Irradiance [mW/cm <sup>2</sup> ]	35.385 mW/cm <sup>2</sup> - 35 W/cm <sup>2</sup>			
Beam area [cm <sup>2</sup> ]	0.002826 cm <sup>2</sup>			
Exposure time [s]	30 seconds per point			
Radiant exposure [J/cm <sup>2</sup> ]	1.061 J/cm <sup>2</sup>			
Radiant energy [J]	3 J			
Number of irradiated points	6 points per tooth divided into: Vestibular (1 apical, 1 middle, and 1 cervical) and palatal			
Application technique	In contact, at a 90-degree angle to the surface			
Number of sessions and frequency	One time only			

16

17 Table 1: Dosimetric Parameters

18

It is made available under a CC-BY 4.0 International license .

Control Group – RAR + FBM simulation (n=22): Simulation of the use of FBM will be carried 1 out identically to the Experimental group. The person responsible for applying the FBM will 2 3 simulate irradiation by positioning the devices in the same locations described for the FBM group, 4 however, the laser pointer will be turned off and the sound of the device will be recorded to mimic 5 the use of the equipment, so, participants will not identify to which group they are part of. In this trial, we have no criteria for discontinuing or modifying allocated interventions because no harm 6 7 is expected with this intervention. The study flowchart presents the details of the project (Figure 4). 8

9 Relevant concomitant care and interventions that are permitted or prohibited during the trial –

10 patients should not take analgesics for dentin hypersensitivity other than paracetamol. Any other

11 mediation (described in the exclusion criteria) will influence the analgesic count in the evaluated

12 period.

13 *Primary outcome* 

Pain - It will be evaluated through the application of the Visual Analog (VAS) with a 10cm ruler 14 in length of 10 cm, with no mark. One of the extremes is marked "0", and the other "100" which 15 16 means respectively "no pain" and "unbearable pain". This rule will be the same for all 17 participants. Instructions on marking will always be given to the patient by the same operator. 18 Each participant will be instructed to mark with a vertical line the point that best corresponds to 19 the intensity of pain at the time of assessment (Bottega, 2010). Without the presence of the 20 participant, the operator will measure this mark with the same ruler, recording this data on the research clinical record. This analysis will occur on all periods (baseline, 7, and 30 days). 21

22 Secondary outcomes

*Rescue medication* - Another parameter analyzed will be the quantity of analgesics ingested, as proposed by Bauer, 2013. At the beginning of the research, a pack of paracetamol<sup>®</sup> will be given to each participant (Jóźwiak-Bebenista, 2014) and the use will be prescribed in case of pain. At the end of the experiment, the number of pills will be evaluated as another pain measurement parameter (drug tablet return). To monitor the participant's adherence they will be asked to take the pack of analgesics to each consultation checking how they will be used. The participant will be oriented to use only paracetamol, not other medicines.

30 *Analysis of the impact of oral health on the individual's quality of life through the application of* 

31 *the OHIP-14 questionnaire (Oral health impact profile questionnaire - Ohip-14)-* The Ohip-14

32 will be used to assess the impact of oral health on the participant's quality of life (Slade, 1997).

33 To quantify the Likert scale, we will use the additive method – Points will be summed (0-56),

34 with 56 having the greatest impact on quality of life. This is validated and translated into a

35 Portuguese questionnaire (Riva, 2022).

1 Any changes in the protocol will be communicated to the Ethics Committee.

2 Analysis of results - Initial descriptive analyses will consider all the variables measured in the study, both quantitative (mean and standard deviation) and qualitative (frequencies and 3 4 percentages). Subsequently, normality analyses will be performed to determine the appropriate 5 statistical tests for each data set and the appropriate statistical tests will be applied for each specific analysis. In all tests, the significance level of 5% of probability or the corresponding p-6 7 value will be adopted. All analyses will be performed using the statistical program SPSS for 8 Windows, version 9.1. The data of all patients randomized for the research will be included in the 9 statistical analysis, described, and discussed, as well as the possible adverse effects. Adverse 10 events will be questioned for all participants during the experiment. However interim analyses 11 will not plan because adverse events are not expected in this trial.

12

#### 13 **References**

14

Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, Flemmig TF, Garcia R,
Giannobile WV, Graziani F, Greenwell H, Herrera D, Kao RT, Kebschull M, Kinane DF,
Kirkwood KL, Kocher T, Kornman KS, Kumar PS, Loos BG, Machtei E, Meng H, Mombelli A,
Needleman I, Offenbacher S, Seymour GJ, Teles R, Tonetti MS. Periodontitis: Consensus report
of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and PeriImplant Diseases and Conditions. J Periodontol. 2018 Jun;89 Suppl 1:S173-S182. doi:
10.1002/JPER.17-0721. PMID: 29926951.

22

Alpiste Illueca FM, Buitrago Vera P, de Grado Cabanilles P, Fuenmayor Fernandez V, Gil Loscos
FJ. Periodontal regeneration in clinical practice. Med Oral Patol Oral Cir Bucal. 2006 Jul
1;11(4):E382-92. English, Spanish. PMID: 16816809.

26

Amaro R, Ilusión M; Escalona L, Acevedo, AM.Teorías y fatores etiológicos involucrados en la
hipersensibilidad dentinaria. Acta odontol. venez [online]. 2009, vol.47, n.1, pp. 260-269. ISSN 0001-6365.

30

31 Sobral M, Garone Netto N, Luz M, Santos A. Aspectos clínicos da etiología da

- 32 hipersensibilidade dentinaria cervical. Rev Odontol Univ Sao Paulo 1999; 13(2)189-195.
- 33

Hastings C. Hipersensibilidad dentinaria, higiene dental y consideraciones periodontales. Int Dent
 J 2002; 52: 385-393.

36

Raut CP, Sethi KS, Kohale BR, Mamajiwala A, Warang A. Indocyanine green-mediated
photothermal therapy in treatment of chronic periodontitis: A clinico-microbiological study. J
Indian Soc Periodontol. 2018 May-Jun;22(3):221-227. doi: 10.4103/jisp.jisp\_128\_18. PMID:
29962701;

41

Fischer C, Fischer RG, Wennberg A. Prevalence and distribution of cervical dentine 1 2 hypersensitivity in a population in Rio de Janeiro, Brazil. J Dent. 1992 Oct;20(5):272-6. doi: 10.1016/0300-5712(92)90043-c. PMID: 1452864. 3 4 5 Corona SA, Nascimento TN, Catirse AB, Lizarelli RF, Dinelli W, Palma-Dibb RG, Clinical 6 evaluation of low-level laser therapy and fluoride varnish for treating cervical dentinal 7 hypersensitivity. J Oral Rehabil. 2003 Dec;30(12):1183-9. doi: 10.1111/j.1365-8 2842.2003.01185.x. PMID: 14641661. 9 10 Ladalardo TC, Pinheiro A, Campos RA, Brugnera Júnior A, Zanin F, Albernaz PL, Weckx LL. Laser therapy in the treatment of dentine hypersensitivity. Braz Dent J. 2004;15(2):144-50. doi: 11 10.1590/s0103-64402004000200011. Epub 2005 Mar 11. PMID: 15776198. 12 13 14 Sgolastra F, Petrucci A, Severino M, Gatto R, Monaco A. Lasers for the treatment of dentin 15 hypersensitivity: a meta-analysis. J Dent Res. 2013 Jun;92(6):492-9. doi: 16 10.1177/0022034513487212. Epub 2013 Apr 22. PMID: 23609160. 17 18 Sgolastra F, Petrucci A, Gatto R, Monaco A. Effectiveness of laser in dentinal hypersensitivity treatment: a systematic review. J Endod. 2011 Mar;37(3):297-303. doi: 19 20 10.1016/j.joen.2010.11.034. PMID: 21329811. 21 22 Ko Y, Park J, Kim C, Park J, Baek SH, Kook YA. Treatment of dentin hypersensitivity with a 23 low-level laser-emitting toothbrush: double-blind randomized clinical trial of efficacy and 24 safety. J Oral Rehabil. 2014 Jul;41(7):523-31. doi: 10.1111/joor.12170. Epub 2014 Apr 10. 25 PMID: 24717149. 26 27 Sealed Envelope Ltd. 2021. Create a blocked randomization list. [Online] Available from: 28 https://www.sealedenvelope.com/simple-randomiser/v1/lists [Accessed 2 Sep 2022]. 29 30 Bauer HC, Duarte FL, Horliana AC, Tortamano IP, Perez FE, Simone JL, Jorge WA. 31 Assessment of preemptive analgesia with ibuprofen coadministered or not with dexamethasone in third molar surgery: a randomized double-blind controlled clinical trial. Oral Maxillofac 32 33 Surg. 2013 Sep;17(3):165-71. doi: 10.1007/s10006-012-0360-7. Epub 2012 Sep 5. PMID: 22949122. 34 35 36 Jóźwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety 37 concern. Acta Pol Pharm. 2014 Jan-Feb;71(1):11-23. PMID: 24779190. 38 39 Slade GD. Derivation and validation of a short-form oral health impact profile. Community 40 Dent Oral Epidemiol. 1997 Aug;25(4):284-90. doi: 10.1111/j.1600-0528.1997.tb00941.x. PMID: 9332805. 41 42 43 Riva F, Seoane M, Reichenheim ME, Tsakos G, Celeste RK. Adult oral health-related quality of

44 life instruments: A systematic review. Community Dent Oral Epidemiol. 2022 Oct;50(5):333-


45 338. doi: 10.1111/cdoe.12689. Epub 2021 Aug 18. PMID: 34409626.



medRxiv preprint doi: https://doi.org/10.1101/2023.09.28.23296306; this version posted October 1, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available in the certified by peer review is the author/funder. The results of the results



Figure 4. Study flowchart



Randomization

T0 - baseline assessments

EVA, OHIP-14, delivery of analgesic pack

PBM SIMULATION (n=22) T0 - baseline assessments

EVA, OHIP-14, delivery of analgesic pack

PBM (n=22)

7th day of evaluation

EVA, verification of the number of analgesics ingested. 7th day of evaluation

EVA, verification of the number of analgesics ingested.

30th day of evaluation

EVA, OHIP-14, verification of the number of analgesics ingested. 30th day of evaluation

EVA, OHIP-14, verification of the number of analgesics ingested.

		STUDY PERIOD						
		RECORD	RANDOMIZA TION		POS RATIVE	CLOSURE		
TIME RECORD: Inclusion/exclusion criteria Informed consent Research calibration medRxiv preprint coi: Assignment 101/2023.09.28.23 preprint (which with a second of the se	TIME	-T1	0	$T_0$	T <sub>1</sub> (7 d)	T <sub>3</sub> (30 d)		
	RECORD:							
		x						
	Informed consent	х						
	Research calibration	х						
	oi: Aussigner 101/2023.09.28.232963	06; this version posted	Dctober 1, 2023 The copyright	holder for this				
	per INTERVIE is made available under a	centres, who has grante petuity. CC-BY 4.0 Internationa	license .					
	Experimental group			х				
	Control group			х				
	OUTCOMES:							
	VAS (primary)			х	х	х		
	Analgesics			х	х	x		
	OHIP-14			X		х		